Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma
NCT02944708Phase 3Unknown
- Sponsor
- Shanghai Proton and Heavy Ion Center
- Start
- Oct 2015
- Primary completion
- Oct 2018
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of tegafur, capecitabine and tegafur + uracil in nasopharyngeal carcinoma (NPC) (3 arms), sponsored by Shanghai Proton and Heavy Ion Center. Primary endpoint: Progression-free survival at 3 years. Status: unknown.
02
Drugs
tegafurcapecitabinetegafur + uracil
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02944708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02944708.